⌘K
t
AOTI, Inc. held its Annual General Meeting on 25 June 2025, at which all 10 resolutions proposed to shareholders were passed on a poll. These resolutions included the appointment of Douglas Le Fort, Michael Griffiths, Anthony Bourne, Richard Cotton, Ceri Morgan, and Jayesh Pankhania as directors, the re-appointment of Grant Thornton (Ireland) as auditor with 98.88% of votes for, and the passing of a special resolution to disapply pre-emption rights with 99.56% of votes for. Additionally, Anthony Moffat stepped down as a Director but remains COO, and the company confirmed 106,359,163 Common shares were in issue as of 25 June 2025.
| Date | 25 Jun 2025 |
| Time | 13:24:06 |
| Category | AGMs and other meetings |
| ID | 4109O |
25 June 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
Result of Annual General Meeting
The Annual General Meeting of AOTI, INC. was held at Temple Chambers, 3 - 7 Temple Avenue, EC4Y 0DT on 25 June 2025 at 10:00 a.m.
All 10 resolutions put to members were passed on a poll. Resolutions 1-9 were passed as ordinary resolutions and resolution 10 was passed as a special resolution.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To receive and adopt the statement of accounts for the year ended 31 December 2024 together with the reports of the Directors and the auditors thereon. |
73,445,182 |
99.49 |
378,787 |
0.51 |
1,688,157 |
|
Resolution 2 (Ordinary) To appoint Douglas Le Fort as a director of the Company |
74,873,339 |
99.15 |
638,787 |
0.85 |
0 |
|
Resolution 3 (Ordinary) To appoint Michael Griffiths as a director of the Company |
75,512,126 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 4 (Ordinary) To appoint Anthony Bourne as a director of the Company |
75,512,126 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 5 (Ordinary) To appoint Richard Cotton as a director of the Company |
75,133,339 |
100.00 |
0 |
0.00 |
378,787 |
|
Resolution 6 (Ordinary) To appoint Ceri Morgan as a director of the Company |
75,512,126 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 7 (Ordinary) To appoint Jayesh Pankhania as a director of the Company |
75,512,126 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 8 (Ordinary) To re-appoint Grant Thornton (Ireland) as auditor of the Company |
74,664,682 |
98.88 |
847,444 |
1.12 |
0 |
|
Resolution 9 (Ordinary) To authorise the Directors to determine the fees payable to the auditor |
67,956,008 |
90.33 |
7,270,813 |
9.67 |
285,305 |
|
Resolution 10 (Special) To disapply pre-emption rights generally |
66,599,498 |
99.56 |
295,455 |
0.44 |
8,617,173 |
As previously disclosed in the Admission Document in June 2024 Anthony Moffat did not seek re-election at the Annual General Meeting and has stepped down from his role as a Director of the Company. Anthony Moffat will continue in his current role as COO of the Company.
As at 25 June 2025, there were 106,359,163 Common shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
ENDS
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer |
+44 (0)20 3727 1000 |
|
Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel |
+44 (0)20 7418 8900 |
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net